Fermenta Biotech Reports Significant Growth Amid Mixed Financial Performance in June 2025

Fermenta Biotech has reported its financial results for the quarter ending June 2025, revealing notable developments within the company. The financial performance has shown significant growth in key areas, with Profit Before Tax (PBT) reaching Rs 19.32 crore, reflecting a year-on-year increase of 320.80%. Similarly, Profit After Tax (PAT) has surged to Rs 21.83 crore, marking a remarkable growth of 475.1% compared to the previous year. Net sales also demonstrated a strong upward trend, amounting to Rs 136.26 crore, which is a 74.40% increase year-on-year. On the balance sheet front, Fermenta Biotech has achieved a debt-equity ratio of 0.32 times, the lowest in the last five half-year periods, indicating a consistent reduction in borrowing relative to equity capital. Additionally, cash and cash equivalents have reached their highest level in the last six half-year periods at Rs 71.70 crore, suggesting an improvement in short-term liquidity. However, the company faces challenges as operating cash flow has declined to Rs 40.90 crore, the lowest in three years, indicating a decrease in cash revenues from business operations. Furthermore, non-operating income has peaked at Rs 8.77 crore, raising concerns about the sustainability of this income source. Overall, Fermenta Biotech has experienced evaluation changes in its financial score, reflecting the mixed performance across various metrics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.